Investor Presentaiton

Investor Presentation First six months of 2018 International Operations grew by 8% in H1 2018 mainly driven by insulin Slide 7 IO added sales in local currency by product segment and region Region AAMEO Region J&K 13% Region LATAM Local currency growth 133% 5% IO sales as reported by product segment Region Europe Biopharm (1%) Long-acting insulin¹ 7% Region China 14% 19% 7% Obesity 108% 2% Other Diabetes³ 6% 17% (4%) Fast-acting insulin¹ 3% 11% GLP-1 diabetes 8% 17% 14% Human insulin² (9%) Premix insulin¹ (1%) Reported sales of DKK 27.4 billion (1%) Insulin GLP-1 diabetes Obesity Biopharm Note: numbers in parentheses represent reported growth (H1 2018 vs. H1 2017), ¹ Modern and New- generation insulin, 2 Human insulin covers all insulin segments, 3 Other Diabetes Care primarily covers NovoNormⓇ, needles and GlucaGen® HypoKitⓇ IO: International Operations LATAM: Latin America AAMEO: Africa, Asia, Middle East & Oceania J&K: Japan & Korea novo nordisk

View entire presentation